Hormonal
Serum resistin concentrations are not significantly correlated with insulin sensitivity (glucose disposal rate) in obese or obese diabetic humans, indicating resistin is unlikely to be a major mediator of insulin resistance in these populations.
For individuals with obesity or type 2 diabetes, serum resistin levels are not a reliable indicator of insulin sensitivity, nor is lowering resistin likely to be a primary strategy for improving insulin resistance. Focus on established interventions like weight management and physical activity rather than targeting resistin specifically.
Serum resistin concentrations were not different among nonobese (4.1 ± 1.7 ng/ml), obese (4.2 ± 1.6 ng/ml), and obese diabetic subjects (3.7 ± 1.2 ng/ml), and were not significantly correlated to glucose disposal rate during a hyperinsulinemic glucose clamp across groups.
Why this rating
High-quality human study using the gold-standard hyperinsulinemic-euglycemic clamp technique, though limited by sample size (n=38 nonobese, n=34 obese/diabetic).
Source
Relationship between Serum Resistin Concentrations and Insulin Resistance in Nonobese, Obese, and Obese Diabetic Subjects
Leonie K. Heilbronn et al. · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2003-031410
More from this paper
- In nonobese humans, there is a weak inverse correlation between serum resistin and insulin sensitivity, but this association disappears when adjusting for body fat percentage.Good
- Serum resistin levels are directly correlated with resistin mRNA expression in abdominal subcutaneous adipose tissue, suggesting adipose tissue is a source of circulating resistin.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →